Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SLC16A3 | O15427 | 7/20 | 0.55 |
| ▸ | SLC16A1 | P53985 | 7/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020681 | 1.00 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL2671455 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL2671454 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL23605194 | 0.87 | EGFR (0.60) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL9360940 | 0.86 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL8649661 | 0.86 | CYP1A2 (0.78) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL28820627 | 0.84 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL15428904 | 0.83 | KDM4E (0.68) | CYP1A2CYP3A4CYP2C9KMT2AKDM4E | |
| SCHEMBL9361090 | 0.82 | KMT2A (0.64) | CYP3A4KMT2AKDM4ELMNAPKM | |
| SCHEMBL9361088 | 0.82 | KMT2A (0.64) | CYP3A4KMT2AKDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
| EP-2203454-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. Organon (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037220-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON (NL) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | CYP1A2 41/4885CYP3A4 71/4885CYP2C9 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.